Massachusetts-based gene-editing biotech company Intellia Therapeutics and New York-based biotech company Regeneron Pharmaceuticals have expanded the existing research collaboration (entered in April 2016) to develop gene-editing therapies for neurological and muscular diseases.
The collaboration will leverage Regeneron's antibody-targeted adeno-associated virus (AAV) vectors and Intellia's Nme2 Cas9 system to modify target genes in non-liver tissues. The companies will initially focus on two non-liver targets, and each company will have the opportunity to lead the development and commercialization of product candidates for one target.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.